Novus Scientific AB

Novus Scientific AB specialises in bioabsorbable synthetic polymer surgical mesh designed for extra-gynaecological applications. These devices are primarily used in reconstructive surgeries, such as pelvic organ prolapse and stress urinary incontinence repairs, where gradual tissue integration and support are needed. The mesh is engineered for techniques like transvaginal and transabdominal approaches.

Novus Scientific AB is headquartered in the United States. The company’s location is relevant for understanding its regulatory and operational context, particularly when reviewing device listings and compliance frameworks.

Novus Scientific AB’s surgical mesh products fall under FDA Class II classification. This designation applies to devices that pose moderate risk and require special controls to ensure safety and effectiveness. Class II devices in the U.S. are typically authorised through pathways like the 510(k) premarket notification, demonstrating substantial equivalence to a legally marketed predicate device.

Novus Scientific AB’s devices are included in the FDA’s 510(k) premarket notification registry and the Unique Device Identifier (UDI) system. These registries track authorised devices and their compliance with U.S. regulatory requirements, ensuring transparency for healthcare providers and oversight agencies. The UDI system, in particular, standardises device identification for traceability.

The 510(k) pathway is used for Class II devices like Novus Scientific AB’s surgical mesh because it demonstrates that the product is substantially equivalent to a legally marketed predicate device. This means the new device has the same intended use, technological characteristics, and performance as an existing authorised device, reducing the need for extensive clinical trials. The pathway ensures regulatory oversight while streamlining market access for moderately risky devices.